Company Description
Intelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners.
It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities.
The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022.
The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.
| Country | United States |
| Founded | 2016 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 51 |
| CEO | Harry Simeonidis |
Contact Details
Address: 142 West 57th St Fl11 New York, New York 10019 United States | |
| Phone | 646-233-6971 |
| Website | gbs.inc |
Stock Details
| Ticker Symbol | INBS |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001725430 |
| ISIN Number | US36151G6008 |
| Employer ID | 82-1512711 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Harry Simeonidis | President and Chief Executive Officer |
| Spiro Kevin Sakiris B.Bus, C.A., CA, Dip Law | Chief Financial Officer |
| Victoria Gavrilenko | Operations Manager |
| Alex Arzeno | Vice President of Investor Relations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 18, 2024 | 8-K | Current Report |
| Apr 12, 2024 | 8-K | Current Report |
| Apr 9, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 424B3 | Prospectus |
| Mar 27, 2024 | EFFECT | Notice of Effectiveness |
| Mar 25, 2024 | UPLOAD | Filing |
| Mar 22, 2024 | D | Notice of Exempt Offering of Securities |
| Mar 18, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 18, 2024 | 424B3 | Prospectus |
| Mar 15, 2024 | EFFECT | Notice of Effectiveness |